Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
Once an FDA-approved drug, now available only as a compounded product — for reasons that are more about business than safety.
Sermorelin has an unusual history worth knowing: it was an FDA-approved drug, and the approval was withdrawn — but not for safety reasons. Here's the actual timeline, and what its current status means for you.
Sermorelin was FDA-approved in 1990 as a diagnostic agent and again in 1997 (as Geref) to treat idiopathic growth hormone deficiency in children. In 2008, the manufacturer discontinued it for business reasons and asked the FDA to withdraw the approval — and the FDA's own 2013 determination explicitly states this was not a safety or effectiveness finding. Today, all sermorelin is compounded rather than sold as an FDA-approved finished product, but it remains in the FDA's Category 1 — legal for licensed pharmacies to compound with a valid prescription.
Like tesamorelin, sermorelin stimulates the pituitary to release the body's own growth hormone rather than replacing it directly, working with — not around — the body's natural pulsatile release pattern and feedback regulation.
The historical FDA approval was built on real trial data for its original pediatric indication. Its current off-label use in adults (general GH-axis support, recovery, sleep, body composition) rests on a mix of the older approval data, mechanistic reasoning, and a smaller body of adult-focused research — a meaningfully different evidence bar than an active adult-indication approval.
Generally well-tolerated; the most common issues are injection-site reactions and transient flushing or headache. As with any GH-axis compound, it warrants caution in anyone with active malignancy (since growth hormone can support tissue growth broadly) and requires a provider to evaluate pituitary and metabolic health first.
Sermorelin's compounded-only status often gets mistaken for a red flag; the actual history is a business discontinuation, not a safety pull. That said, "not a red flag" isn't the same as "current adult-indication approval" — off-label use should still go through the same lab-first, provider-managed process as everything else here.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense sermorelin or any medication.